Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial

Author(s): Yasir Y Elamin 1, Jacqulyne P Robichaux 1, Brett W Carter 2, Mehmet Altan 1, Don L Gibbons 1, Frank V Fossella 1, Vincent K Lam 1 3, Anisha B Patel 4, Marcelo V Negrao 1, Xiuning Le 1, Frank E Mott 1, Jianjun Zhang 1, Lei Feng 5, George Blumenschein Jr 1, Anne S Tsao 1, John V Heymach 1
Source: J Clin Oncol. 2022 Mar 1;40(7):702-709. doi: 10.1200/JCO.21.01113
Lucio Gordan MD

Dr. Lucio Gordan's Thoughts

Another trial corroborating the activity of poziotinib in this setting.

PURPOSE

Targeted therapies against non–small-cell lung cancer (NSCLC) harboring HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of poziotinib in patients with HER2 exon 20 mutant advanced NSCLC in a single-arm, open-label, phase II study.

PATIENTS AND METHODS

Patients with advanced HER2 exon 20 mutant NSCLC were enrolled to receive poziotinib at a dose of 16 mg/d for 28-day cycles. The primary end point was objective response rate per RECIST version 1.1. Confirmatory scans were performed at least 28 days from initial radiologic response.

RESULTS

Thirty patients received poziotinib treatment. At baseline, 90% of patients received prior platinum-based chemotherapy and 53% had two lines or more prior systemic therapies. As of data cutoff on March 1, 2021, the confirmed objective response rate was 27% (95% CI, 12 to 46). Responses were observed across HER2 exon 20 mutation subtypes. The median duration of response was 5.0 months (95% CI, 4.0 to not estimable). The median progression-free survival was 5.5 months (95% CI, 4.0 to 7.0). The median overall survival was 15 months (95% CI, 9.0 to not estimable). The most common grade 3 treatment-related adverse events were skin rash (47%) and diarrhea (20%). There was one possible treatment-related death because of pneumonitis.

CONCLUSION

Poziotinib showed promising antitumor activity in patients with HER2 exon 20 mutant NSCLC including patients who had previously received platinum-based chemotherapy.

Author Affiliations

1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.2Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX.3Department of Medicine, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD.4Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX.5Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: A retrospective study from community oncology practices

FCS medical oncologist and hematologist Lowell L. Hart, MD, FACP was first-author a study with FCS co-authors President and Managing Physician Lucio N. Gordan, MD, Director of Pharmacy Operations Kristen Boykin, Senior Vice President & Data Officer Trevor Heritage, PhD, and (Retired) Vice President of Pharmacy Services Ray Bailey BPharm, RPh, that evaluated ES-SCLC patients with chemotherapy-induced myelosuppression over a seven-year period, from January 2013 through December 2020. Within this cohort, 98% of the patients experienced at least one myelosuppressive episode following chemotherapy treatment, leading to the need for supportive care, creating additional costs in health care management and time lost in treatment for ES-SCLC.

Read More »

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study

Suddenly met-NSCLC is a crowded space.  This study did not conclude that T+D+CT was better than D+CT, the findings showed that D+CT was better than CT alone.  The addition of T to D+CT improved the PFS and OS trend but I don’t think this was a homerun result.  There was not a significant OS benefit and further follow-up will declare these results.  Also an improved outcomes were not seen in the non-squamous population.  The pembrolizumab studies have 5+ years of follow-up and an improvement in PFS and OS across NSCLC subtypes.

Read More »